|

Docetaxel Clinical Trials

145 actively recruiting trials across 44 locations

▼ -2 trials since August 2026

Also known as: AK112, Brand of drug is based on institutional procurement, C43H53NO14∙3H2O, Cisplatin, Transoral robotic surgery, Docecad +15 more

Pipeline

Phase 1: 15Phase 2: 46Phase 3: 47Phase 4: 2Phase 1/2: 20Phase 2/3: 7

Top Sponsors

  • Merck Sharp & Dohme LLC6
  • Shanghai Jiao Tong University School of Medicine4
  • Memorial Sloan Kettering Cancer Center4
  • BioNTech SE4
  • University of Washington3

Indications

Other64 trials

A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination With HLX07 Versus Docetaxel in Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
Phase 2/3
A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours
Phase 1/2
A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC
Phase 3
A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer
Phase 3
A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combined With Chemotherapy in Lung Cancer
Phase 1
A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers
Phase 1/2
A Phase Ib/II Trial of Neoadjuvant Zolbetuximab Plus Docetaxel, Oxaliplatin and S-1 Chemotherapy in Patients With Locally Advanced Gastric Cancer
Phase 1/2
A Prospective, Open, Multicenter Single-arm Clinical Studie of Docetaxel, Carboplatin Combined With Inetetamab and Pyrotinib in the Treatment of Local-advanced HER2-positive Breast Cancer
N/A
A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy.
Phase 2
A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer
Phase 3
A Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer
Phase 1
A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment
Phase 3
A Study for the Adjuvant Treatment of Breast Cancer
Phase 4
A Study for the Neoadjuvant Treatment of Breast Cancer
Phase 4
A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer
Phase 3
A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer
Phase 2/3
A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer
Phase 3
A Study to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D Mutation
Phase 3
AK129 Combination Therapy for Advanced Solid Tumors
Phase 1/2
Adjuvant Chemotherapy for High Malignant Prostate Cancer
An Exploratory Study of Tislelizumab in Combination with Chemotherapy in Immuno-experienced Patients with EGFR/ALK/ROS1-negative Advanced NSCLC in the Second-line Setting
Phase 2
An Open Label Phase 2 Study of Total Neoadjuvant Therapy (TNT) Consisting of FLOT With Pembrolizumab and Short Radiation for Patients With Locally Advanced Gastroesophageal Junction Adenocarcinoma
Phase 2
Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery
Phase 2
Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC
Phase 3
Comparing the Safety and Efficacy of First-line Polychemotherapy and Polychemotherapy in Combination With PIPAC Sessions
Phase 2
DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)
Phase 1/2
Docetaxel, Oxaliplatin and 5-FU for Gastric Cancer With Inoperable Malignant Bowel Obstruction
Phase 2
EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer
Phase 3
Ebastine in Combination With Docetaxel as a Treatment for Castration-resistant Metastatic Prostate Cancer
Phase 1/2
Effect of NST Whole-course Nutritional Management on Nutritional Status and Adverse Reactions in Esophageal Cancer
N/A
Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer
Phase 2/3
Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.
Phase 3
Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC
Phase 3
Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Agent (Alone or Combined) or Radiotherapy on Primary Tumor in Addition to Androgen Deprivation Therapy in HOrmone-Sensitive Metastatic Prostate Cancer Patients
Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC
Phase 1
Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)
Phase 2
HIPEC + FLOT vs. FLOT Alone in Patients With Gastric Cancer and GEJ (PREVENT)
Phase 3
IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer
Phase 3
Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure
Phase 2
Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC
Phase 2/3
Neoadjuvant Pyrotinib-to-pertuzumab in HER2+ eBC
Phase 3
Oncological Benefits of Pressured Intraperitoneal Aerosol Chemotherapy (PIPAC) in Patients With T3-4 Gastric Cancer Cyt-
N/A
Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer
Phase 2
Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide: REINFORCE Trial.
Phase 3
Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer
Phase 3
Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes
Phase 3
Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer
Phase 2
SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC
Phase 2
Savolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wildtype NSCLC With MET Overexpression
Phase 1/2
Sequential Gemcitabine Plus Docetaxel Versus Gemcitabine Plus Mitomycin C for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer
Phase 2
Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer
Phase 1/2
Study of Comparing of With and Without Sequential Therapy of S-1
Phase 3
TCb vs EC-T in High Risk ER+/HER2- Breast Cancer
Phase 3
Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated
Phase 3
The Management of Metastatic Neck Nodes in N2/3 Hypopharyngeal Squamous Cell Carcinoma
N/A
Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer
Phase 2/3
Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer
Phase 2
Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers
Phase 2/3
Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer
Phase 2
Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy
Phase 2
Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer
Phase 3
WAST Cell-Docetaxel Combination Therapy in PD-1 Inhibitor-Resistant Advanced NSCLC
Phase 2
ctDNA in HER2+ EBC Neoadjuvant Treatment
Phase 2
ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)
Phase 2

Birmingham, Alabama7 trials

A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer

Childrens Hospital of Alabama

Phase 2
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

University of Alabama at Birmingham - Main /ID# 247074

Phase 3
Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment

The University of Alabama at Birmingham Hospital

Phase 2
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

University of Alabama at Birmingham Cancer Center

Phase 3
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

Alabama Oncology

Phase 3
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

University of Alabama at Birmingham Cancer Center

Phase 2
Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC

University of Alabama at Birmingham (O'Neal Comprehensive Cancer Center)

Phase 2

Phoenix, Arizona5 trials

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

Mayo Clinic in Arizona - Phoenix ( Site 0044)

Phase 3
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

Local Institution - 0005

Phase 2
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

Cancer Center at Saint Joseph's

Phase 3
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)

Mayo Clinic Hospital

Phase 3
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

Exelixis Clinical Site #67

Phase 1

Boston, Massachusetts5 trials

A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer

Massachusetts General Hospital (Data Collection Only)

Phase 2
PDT For Induction Therapy For Head And Neck Cancer

Massachusetts General Hospital

Phase 2
Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC

Brigham and Women's Hospital

Phase 2
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

Dana-Farber Cancer Institute

Phase 2
Toripalimab With Chemotherapy for Sinus Cancer

Brigham and Women's Hospital

Phase 2

Duarte, California4 trials

A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases

City of Hope

Phase 3
A Study of ASP3082 in Adults With Advanced Solid Tumors

City of Hope National Medical Center

Phase 1
Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial

City of Hope Medical Center

Phase 2
Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer

Research Site

Phase 1/2

Los Angeles, California4 trials

A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)

UCLA Hematology & Oncology ( Site 0003)

Phase 1/2
A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors

START Los Angeles, LLC

Phase 1/2
A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer

VA West Los Angeles Medical Center - (CRS) - NAVREF - PPDS

Phase 2
Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer

Cedars-Sinai Medical Center

Phase 2

Houston, Texas4 trials

Immunotherapy With Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Paranasal Sinuses (I-NAPA)

M D Anderson Cancer Center

Phase 2
NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer

M D Anderson Cancer Center

Phase 1
Prospective Observational Study of Outcomes After Gemcitabine, Docetaxel, Melphalan, and Carboplatin With Autologous Stem Cell Transplantation in Pediatric Relapsed/Refractory Germ Cell Tumors

MD Anderson Cancer Center

Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma

UT MD Anderson Cancer Center

Phase 1/2

Tucson, Arizona3 trials

A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer

Center for Neurosciences

Phase 3
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

Research Site

Phase 3
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

Banner University Medical Center - Tucson

Phase 3

Chicago, Illinois3 trials

BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer

University of Illinois

Phase 2
LUNG-05: Investigating Chemotherapy Effectiveness for Non-Small Cell Lung Cancer (NSCLC) Metastatic Patients

University of Illinois Cancer Center

N/A
Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies

The University of Chicago

Phase 1

New York, New York3 trials

A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.

Columbia University Irving Medical Center

Phase 1/2
Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)

Laura & Isaac Perlmutter Cancer Center at NYU Langone Health

Phase 3
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma

Memorial Sloan Kettering Cancer Center

Phase 1/2

Seattle, Washington3 trials

A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer

Fred Hutch/University of Washington Cancer Consortium

Phase 2
Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer

Fred Hutch/University of Washington Cancer Consortium

Phase 2
Measuring Circulating Tumor Deoxyribonucleic Acid Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation in Patients With Metastatic Castration-Resistant Prostate Cancer, DYNAMO Trial

Fred Hutch/University of Washington Cancer Consortium

Phase 2

Chandler, Arizona2 trials

A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

Arizona Clinical Trials

Phase 3
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

Research Site

Phase 3

Gilbert, Arizona2 trials

FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors

Banner MD Anderson Cancer Center

Phase 1
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

Banner MD Anderson Cancer Center

Phase 3

Scottsdale, Arizona2 trials

A Study of KK2269 in Adult Participants With Solid Tumors

Mayo Clinic Arizona

Phase 1
De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA

Mayo Clinic in Arizona

Phase 2

New Haven, Connecticut2 trials

A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

Yale University School of Medicine

Phase 3
A Study of ASP1002 in Adults for Treatment of Solid Tumors

Yale University Cancer Center

Phase 1

Jacksonville, Florida2 trials

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors

Mayo Clinic Jacksonville

Phase 1
In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial

Mayo Clinic in Florida

Phase 1/2

Lexington, Kentucky2 trials

Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer

University of Kentucky Chandler Medical Center

Phase 1
Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)

University of Kentucky Chandler Medical Center ( Site 0019)

Phase 2

Daphne, Alabama1 trial

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis

Phase 2/3

Dothan, Alabama1 trial

A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs

XCancer Research Network/Dothan Hematology & Oncology

Phase 1/2

Mobile, Alabama1 trial

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

University of South Alabama, Mitchell Cancer Institute ( Site 6033)

Phase 3

Anchorage, Alaska1 trial

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

Anchorage Associates in Radiation Medicine

Phase 3

Bullhead City, Arizona1 trial

Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer

Pioneer Research Center, LLC

Phase 2

Goodyear, Arizona1 trial

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

City of Hope Cancer Center Phoenix

Phase 3

Springdale, Arkansas1 trial

Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In

Highlands Oncology Group

Phase 3

Beverly Hills, California1 trial

Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

Clinical Research Advisors, LLC

Phase 3

Clovis, California1 trial

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

Community Cancer Institute

Phase 1/2

Glendale, California1 trial

A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation

Oncura Health d.b.a.Los Angeles Cancer Network

Phase 3

La Jolla, California1 trial

Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)

UCSD Moores Cancer Center ( Site 0039)

Phase 1/2

Long Beach, California1 trial

A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

Oncology Institute

Phase 2

Orange, California1 trial

The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

Chao Family Comprehensive Cancer Centre

Phase 3

Sacramento, California1 trial

Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer

University of California Davis

Phase 2

Aurora, Colorado1 trial

A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

Rocky Mountain Cancer Centers

Phase 3

Washington D.C., District of Columbia1 trial

A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)

Sibley Memorial Hospital ( Site 0849)

Phase 3

Gainesville, Florida1 trial

Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer

University of Florida

Phase 2

Sarasota, Florida1 trial

A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer

Florida Cancer Specialists

Phase 1

Tampa, Florida1 trial

MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors

Moffitt Cancer Center

Phase 1

Jeffersonville, Indiana1 trial

A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)

First Urology PSC

Phase 3

Fairway, Kansas1 trial

Trial of Neoadjuvant THP vs TCHP for HER2-Amplified/Positive Breast Cancer

The University of Kansas Cancer Center (KUCC)

Phase 2

Baltimore, Maryland1 trial

A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)

Johns Hopkins University (Data Collection Only)

Phase 3

Bethesda, Maryland1 trial

A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer

National Institutes of Health Clinical Center

Phase 1/2

Basking Ridge, New Jersey1 trial

A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

Phase 1

Elizabeth, New Jersey1 trial

Optimize Neoadjuvant Therapy in HER2-Positive Early-Stage Breast Cancer

RWJBarnabas Health - Trinitas Hospital and Comprehensive Cancer Center

Phase 2

Huntersville, North Carolina1 trial

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

Carolina BioOncology Institute

Phase 1/2

Philadelphia, Pennsylvania1 trial

Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer

Fox Chase Cancer Center

Phase 2

Pittsburgh, Pennsylvania1 trial

Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design

UPMC Hillman Cancer Center - Radiation Oncology

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.